Oxidopamine-d4 (6-Hydroxydopamine-d4) hydrobromide is the deuterium labeled Oxidopamine hydrobromide. Oxidopamine (6-OHDA) hydrobromide, an antagonist of the neurotransmitter dopamine, is a widely used neurotoxin that selectively destroys dopaminergic neurons.

Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs^[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

254.11

C₈H₈D₄BrNO₃

2733842-05-0

6-羟基多巴胺氢溴酸盐 d4 (氢溴酸盐)

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.

  [2]. Fujita H et al. Cell-permeable cAMP analog suppresses 6-hydroxydopamine-induced apoptosis in PC12 cells through the activation of the Akt pathway. Brain Res. 2006 Oct 3;1113(1):10-23.

  [3]. Soto-Otero R et al. Autoxidation and neurotoxicity of 6-hydroxydopamine in the presence of some antioxidants: potential implication in relation to the pathogenesis of Parkinson’s disease. J Neurochem. 2000 Apr;74(4):1605-12.